• In cases in which an autogenous vein is not available, the venous allograft still represents an interesting alternative; however, early occlusion of the allograft is the rule. Forty-five mongrel dogs received jugular allografts transplanted into the carotid artery. Group 1 (n=6) received no immunosuppression; group 2 (n=5) received systemic azathioprine (2.5 mg/kg/day). In group 3 (n = 10) the grafts were pretreated with cyclosporine at 4°C, and in group 4 (n = 9) the grafts were cryopreserved in a solution of 15% dimethyl sulfoxide and cyclosporine (50 mg/L) at—196 °C prior to implantation. Groups 3 and 4 received azathioprine as in group 2. Group 5 received cyclosporine systemically (15 to 20 mg/kg/day). Patency rates at one month (groups 1 and 2, 0%; group 3, 57.1%; groups 4 and 5,100%) indicate that cyclosporine improves venous allograft survival both when used systemically and as a graft pretreatment modality.
(Arch Surg 1983;118:829-833)
Bandlien KO, Toledo-Pereyra LH, MacKenzie GH, Choudhury SP, Cortez JA. Immunosuppression With Cyclosporine: A New Approach to Improve Patency of Venous Allografts. Arch Surg. 1983;118(7):829–833. doi:10.1001/archsurg.1983.01390070039008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: